What are the most common long-term side effects of Ozempic?

Gastrointestinal issues — nausea, diarrhea, constipation, and bloating — remain the most frequent side effects across every duration of treatment, though most patients adapt within the first 8 to 12 weeks after each dose escalation. Less common but more serious long-term concerns include gallbladder disease from rapid weight loss, acute pancreatitis, and potential loss of lean muscle mass. Cardiovascular outcomes on semaglutide are generally favorable.

Does Ozempic really cause thyroid cancer?

The boxed warning is based on rodent studies, not confirmed human data. A 2024 systematic review of over 14,000 semaglutide patients found thyroid cancer incidence under 1% with no statistically significant elevation above baseline. Meta-analyses show a non-significant odds ratio with wide confidence intervals. Regulators still advise against use in people with personal or family history of medullary thyroid carcinoma or MEN2, but for the general population the human evidence remains reassuring.

Is it safe to stay on Ozempic for years?

The longest randomized controlled data comes from the SELECT trial at four years, which found sustained weight loss and fewer serious adverse events in the semaglutide group than placebo. Real-world prescribing now spans nearly a decade. Multi-decade safety data doesn't yet exist, but the current picture supports long-term use in appropriately selected patients with monitoring.

Can Ozempic cause permanent damage?

Most Ozempic side effects are reversible after stopping the medication. Rare but serious events — pancreatitis, gallbladder disease requiring surgery, or significant muscle loss — can have lasting consequences. Ozempic face, the gaunt facial appearance from fat loss, is partially but not always fully reversible. The most preventable long-term harm is muscle loss, which can be substantially mitigated with resistance training and adequate protein intake.

Should I get regular checkups while on Ozempic long-term?

Yes. Annual bloodwork including a basic metabolic panel, liver function, lipid panel, and A1C (if diabetic or prediabetic) is reasonable. Any new neck lumps, persistent upper abdominal pain, severe vomiting, or mood changes warrant prompt evaluation. If you have diabetic retinopathy, coordinate with an ophthalmologist before starting and during treatment, since rapid glycemic improvements can temporarily worsen retinopathy.

Ozempic Long-Term Side Effects: What We Know So Far

Ozempic was approved by the FDA in 2017. For the first several years after launch, almost all available safety data came from type 2 diabetes trials running one to two years. That left an obvious question: what about year three, four, five, and beyond? People starting this medication in their 40s are looking at potentially decades of use.

That gap has narrowed considerably. The SELECT trial followed patients out to four years. Meta-analyses now pool data from tens of thousands of participants. Post-market surveillance has flagged concerns and, in some cases, dismissed them. Below is what the current evidence actually supports, separated from the viral TikTok claims and the marketing materials.

The Long-Term Safety Picture

The most important recent data point comes from SELECT, a trial of 17,604 adults with cardiovascular disease and overweight or obesity (without diabetes) who took semaglutide 2.4 mg weekly for up to four years. At 208 weeks — roughly four years — participants on semaglutide had lost an average of 10.2% of body weight and 7.8 cm of waist circumference compared to minimal changes in the placebo group. Critically for long-term safety, the semaglutide group had fewer serious adverse events overall than the placebo group. [PubMed: PMID 38740993]

A 2024 meta-analysis in the American Journal of Cardiology pooled four randomized controlled trials covering 3,087 patients without diabetes and found sustained weight loss at long-term follow-up, with most adverse events classified as transient and mild-to-moderate — overwhelmingly gastrointestinal. [PubMed: PMID 38679221]

That's the macro picture. Now the specifics.

1. Gastrointestinal Issues: Common, Usually Transient

Nausea, diarrhea, constipation, and vomiting are the most frequently reported side effects in essentially every semaglutide trial. Rates vary widely depending on dose and how quickly it's titrated, but across a 2024 systematic review of 14,550 participants, nausea was reported in 2.05% to 19.95% of semaglutide users and diarrhea in 1.4% to 13%. [PubMed: PMID 38673931]

For most people, these symptoms peak in the first 4 to 8 weeks after each dose escalation, then settle. A smaller subset — perhaps 3% to 5% — discontinue the drug specifically because GI side effects never fully adapt. If you're three months in and still vomiting regularly, that's a signal worth discussing with your prescriber rather than muscling through.

2. Gastroparesis and Delayed Gastric Emptying

Semaglutide slows gastric emptying — that's part of how it works. For most people, this produces the intended effect: earlier satiety and less hunger. For a minority, it produces something closer to gastroparesis, with prolonged fullness, bloating, nausea, and occasional vomiting of undigested food.

Severe gastroparesis on GLP-1 drugs appears to be relatively uncommon but has drawn regulator attention. The FDA added ileus (intestinal obstruction) as a labeled adverse event in 2023 after reviewing post-market reports. Gastroparesis itself wasn't added as a formal warning, but the FDA acknowledges it has received such reports. People with pre-existing gastroparesis or motility disorders should generally avoid GLP-1 agonists.

3. Pancreatitis

Acute pancreatitis has been reported with all GLP-1 receptor agonists. In randomized trials the absolute rates are low — typically well under 1% — and meta-analyses have produced mixed findings on whether there's a true causal increase above baseline risk in this patient population (many of whom have diabetes, obesity, and gallstones, all independent risk factors for pancreatitis).

The practical takeaway: if you develop severe, persistent upper abdominal pain that radiates to your back, especially with vomiting, stop injecting and get evaluated immediately. A personal history of pancreatitis is generally considered a relative contraindication.

4. Gallbladder Disease

Rapid weight loss of any kind — whether from bariatric surgery, crash dieting, or GLP-1 drugs — increases gallstone formation. Bile becomes more concentrated during rapid weight loss, and gallstones form. Clinical trials of semaglutide consistently report modest increases in gallbladder-related events compared to placebo. For most users the absolute risk is small, but if you have a history of gallstones it's worth flagging with your prescriber.

5. Thyroid C-Cell Concerns

All GLP-1 receptor agonists carry a boxed warning about medullary thyroid carcinoma (MTC) based on rodent studies where GLP-1 agonists caused C-cell tumors in rats. Whether this translates to human risk has been debated since the class first launched.

A 2024 systematic review specifically examining semaglutide concluded the incidence of thyroid cancer in treated patients was less than 1%, with no statistically significant elevation above background. [PubMed: PMID 38673931] A separate meta-analysis looking specifically at semaglutide and cancer outcomes found an odds ratio for thyroid cancer of 2.04 with a 95% confidence interval spanning 0.33 to 12.61 — a wide, non-significant range that reflects the small number of events and ongoing uncertainty. [PubMed: PMID 37531876]

People with a personal or family history of MTC, or with Multiple Endocrine Neoplasia type 2 (MEN2), should not take semaglutide. For everyone else, this remains a theoretical risk that regulatory agencies continue to monitor but that has not been confirmed in human data through almost a decade of use.

6. Cardiovascular Effects (Mostly Favorable)

Semaglutide's cardiovascular record is actually one of its strongest long-term arguments. The SUSTAIN-6 trial showed a statistically significant reduction in major adverse cardiovascular events — cardiovascular death, nonfatal heart attack, and nonfatal stroke — in patients with type 2 diabetes at high cardiovascular risk. The composite outcome occurred in 6.6% of the semaglutide group versus 8.9% of placebo controls. [PubMed: PMID 27633186]

SUSTAIN-6 also flagged one cardiovascular paradox: an increase in diabetic retinopathy complications requiring intervention. This is thought to be tied to rapid improvements in blood sugar in people with pre-existing, poorly controlled retinopathy — a phenomenon seen with intensive insulin therapy as well. If you have retinopathy, your prescriber should coordinate with an ophthalmologist before and during treatment.

7. Muscle Loss and Body Composition

Any significant weight loss — from any cause — includes some lean mass loss. Estimates from GLP-1 trials and imaging studies suggest that roughly 25% to 40% of total weight loss comes from lean tissue, including skeletal muscle. That proportion is comparable to what's seen with dietary weight loss alone, and it can be meaningfully reduced with resistance training and adequate protein intake (generally 1.2 to 1.6 g per kg body weight for people actively losing weight).

The long-term concern is sarcopenia, particularly in older adults who already have lower baseline muscle mass. Clinical trials haven't been designed to answer whether GLP-1 induced muscle loss translates to increased frailty or fracture risk over 5, 10, or 20 years of use. That's an open question the field is actively studying.

8. Mental Health: Initially Alarmed, Mostly Reassured

In 2023, the European Medicines Agency opened a review into whether GLP-1 drugs were associated with suicidal thoughts and self-harm after case reports raised concerns. The FDA conducted its own evaluation. Both agencies concluded that available evidence did not support a causal link. That said, some users report mood changes on these medications. If you have a history of depression or suicidal ideation, monitoring is reasonable, and any new or worsening symptoms warrant a prompt conversation with your prescriber.

9. Kidney Function

Dehydration from persistent vomiting or diarrhea is the main kidney risk on semaglutide, and it's the mechanism behind most reported cases of acute kidney injury in the post-market data. Baseline kidney function generally improves or is unchanged on GLP-1 therapy; it's the GI-driven dehydration that causes problems. Staying hydrated during dose escalations — and pausing the drug during severe GI illness — sharply reduces this risk.

10. "Ozempic Face" and Skin Changes

Rapid fat loss from the face produces a gaunt, aged appearance some dermatologists have labeled "Ozempic face." This isn't unique to Ozempic — any rapid weight loss does it — but the pattern is more visible because of how quickly GLP-1 drugs work compared to lifestyle interventions. Over months to years, the skin and subcutaneous fat layer partially remodel, but pre-loss appearance doesn't always return.

What the Data Still Can't Tell You

Four years of controlled data (SELECT) and a decade of real-world prescribing covers more than most weight-loss drugs ever get. But several questions remain open:

Multi-decade use. If you start Ozempic at 45 and take it until 75, what happens? Nobody yet knows.
Pregnancy and early postpartum effects. Semaglutide should be stopped at least two months before conception per the label. Data on accidental first-trimester exposure is limited.
Bone density over years. Rapid weight loss can affect bone mineral density; the long-term skeletal effects of staying on GLP-1 drugs for years aren't well characterized.
Pediatric and adolescent use. Semaglutide is approved for adolescents with obesity, but decade-scale safety data in this group is still accumulating.

Practical Takeaways

The biggest long-term risk is still the GI system. Most serious side effects trace back to nausea, vomiting, or delayed gastric emptying. If your GI symptoms never settle, something needs to change — dose, titration pace, or drug entirely.
The thyroid risk is real on paper, small in practice. If you don't have MEN2 or a family history of MTC, your absolute risk appears very low, but it's still a reason to get any new neck lump or voice change checked.
Protect muscle mass actively. Resistance training and adequate protein aren't optional if you're going to be on this drug for years.
Cardiovascular benefits are well-established. If you have cardiovascular disease or high risk, that's a net positive worth factoring in.
Stay hydrated, especially during dose increases. Most semaglutide-related kidney events trace back to dehydration, not the drug itself.
Get annual labs. A basic metabolic panel, liver function, lipid panel, and A1C (if relevant) once a year is cheap insurance against missing something early.

Semaglutide isn't a miracle drug without consequences, but nearly a decade of accumulating data suggests the long-term side-effect profile is manageable for most patients — provided they and their prescribers are paying attention.